Dr. Mehmet Oz stepped into the White House briefing room as the stand‑in press briefer and mixed sharp humor with policy updates, calling out Trump Derangement Syndrome while outlining a major expansion of a federal prescription discount platform and stressing a tougher stance on fraud.

‘Treating Stupid Is Really Hard’: Dr. Oz Roasts TDS-Afflicted in His Turn at WH Press Briefing

Since the regular press secretary went on leave, a rotating lineup of officials has handled briefings, and Dr. Oz was the latest to take the podium in the Brady Briefing Room. He used the opportunity to lampoon what he called the debilitating effects of TDS while also delivering concrete program news. The tone shifted back and forth between jocular jabs and detailed policy remarks. Reporters got both a zinger and substance in one session.

When asked about Trump Derangement Syndrome, Oz didn’t sugarcoat it and admitted the problem is real and difficult to treat. He used blunt language to describe the phenomenon and its pervasiveness in certain media and political circles. The moment landed with laughter in the room, but it wasn’t only a punchline. It set the stage for discussing broader topics he oversees at CMS.

https://x.com/townhallcom/status/2061875873377140927

IT’S MORE CONTAGIOUS IN BLUE STATES THAN COVID: Trump Says TDS Is Real — but the Administration Has a Few Hilarious Cures

Oz also pivoted to policy, highlighting the TrumpRx initiative launched earlier this year and announcing a significant expansion to the list of covered drugs. He told reporters the platform will add 160 medications, pushing the catalog to more than 750 drugs overall. That expansion is important because it increases the odds that patients can compare prices and find the best deal at their local pharmacy. The move is presented as a straightforward way to save consumers money without waiting on complex regulations.

BREAKING: CMS Administrator Dr. Mehmet Oz announces a massive expansion to the TrumpRx program, adding 160 more medications to the platform, pushing the total to over 750 drugs.

“We are adding 160 more drugs to this site. Now, the site already has 700 or so or 600 or so, drugs. So it’s going to take it over 750 total.”

“But that is an important number for other reasons. It means the four out of five medications that are picked up by Americans going into that same drug store that I mentioned earlier, now have the opportunity to double check that the price they’re getting in that drugstore, wherever they’re buying it from, is the best price out there.”

Beyond pricing, Oz made clear he sees fraud as a national problem that must be rooted out across programs and agencies. He framed the fight against waste, fraud, and abuse as a priority for the administration and one that requires sustained attention. That theme threaded through his answers about enforcement and oversight. The goal, he said, is to restore accountability and common sense where systems have been gamed.

At one point he used a pointed historical jab to highlight his frustration with entrenched problems and called out prior administrations for policies that he believes contributed to current dysfunction. The quip was delivered with a wink, but his underlying message about fixing systemic issues was earnest. He emphasized that addressing fraud and inefficiency is part of improving care and lowering costs for patients. Those remarks tied back to the expansion of TrumpRx as a consumer-facing reform.

The presentation combined media-ready lines with specific program details, which made the briefing feel both political and managerial at once. Oz balanced theatrical moments with concrete numbers and administrative plans, aiming to show results rather than just rhetoric. He repeatedly returned to the theme of practical solutions that people can use at the pharmacy counter. For those watching, that blend made the appearance memorable.

While some of the session played like a late-night monologue, several exchanges dove into the nuts and bolts of implementation and oversight. Reporters pressed on how the new drug listings would be verified and how fraud prevention would be enforced across programs. Oz answered in plain terms about steps the agency plans to take and why those steps matter to patients. The emphasis remained on transparency and measurable impact.

The rotating briefers experiment has put unexpected personalities in the spotlight, and Oz’s turn was no exception; he threaded humor through policy announcements in a way that drew attention. Observers noted it was a different flavor from the usual press operation, with officials bringing individual style to the podium. That variety has made the briefings more lively and occasionally revealing about internal priorities. It also left people guessing who might appear next.

Who’s next? I vote for Hegseth.

Editor’s Note: Do you enjoy RedState’s conservative reporting that takes on the radical left and woke media? Support our work so that we can continue to bring you the truth.

Join RedState VIP and use promo code FIGHT to receive 60% off your membership.